BOYD
Desconocido
NEW DEAL: New siRNA Nanotherapy for Inflammatory Bowel Diseases targeting Janus kinases
ALAN BOYD CONSULTANTS LIMITED
participó en un
H2020:
H2020-NMBP-2016-2017
Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people....
2016-11-09 - 2021-09-30 | Financiado
2016-11-09 - 2021-09-30 | Financiado
* No se disponen de datos de la empresa actual.